Since there have been no head-to-head comparisons of the two different formulations at prescription dosing, the advisory does not recommend one over the other.įDA-approved prescription omega-3 fatty acid products include Lovaza and its generic (omega-3 fatty acid ethyl esters - EPA 0.465 mg and DHA 0.375 mg/capsule), Omtryg (a similar product but not clinically available), Vascepa (an ethyl ester product consisting of EPA only, chemical term “icosapent ethyl” - EPA 0.98 g/capsule), and Epanova (omega-3 carboxylic acid - EPA 0.55 g and DHA 0.2 g/capsule, not clinically available).Ībout 25% of adults in the U.S. One combines two types of fatty acids, EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). There are two prescription omega-3 fatty acid medications available. Bill Harris is also an author on this advisory.
The AHA Advisory authors summarized the lipid and lipoprotein effects resulting from pharmacological doses of omega-3s EPA and DHA (at 3 grams or greater per day of EPA+DHA) on the basis of new scientific data and availability of prescription omega-3 preparations. “From our review of the evidence from 17 randomized, controlled clinical trials on high triglyceride levels, we concluded that treatment with 4 grams daily of any of the available prescription choices is effective and can be used safely in conjunction with statin medicines that lower cholesterol,” said Ann Skulas-Ray, Ph.D., the lead author of the new science advisory published in the AHA’s journal Circulation.
#Black omega dha kentucky trial
Based on recent clinical trial evidence, it said prescription omega-3 fatty acid medication reduces triglyceride levels by 20-30% among the majority of people who require treatment for high triglyceride levels. On August 19th, the American Heart Association (AHA) released a new advisory about omega-3s and high triglycerides.
0 kommentar(er)
